CGS Stock Overview
Cogstate Limited, a neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cogstate Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.33 |
| 52 Week High | AU$1.87 |
| 52 Week Low | AU$1.13 |
| Beta | 0.13 |
| 1 Month Change | 1.15% |
| 3 Month Change | 8.16% |
| 1 Year Change | -14.24% |
| 3 Year Change | 45.60% |
| 5 Year Change | 430.00% |
| Change since IPO | 165.00% |
Recent News & Updates
Recent updates
The Price Is Right For Cogstate Limited (ASX:CGS)
Jan 17
Is Cogstate Limited (ASX:CGS) Trading At A 29% Discount?
Jul 26Returns Are Gaining Momentum At Cogstate (ASX:CGS)
Apr 14Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%
Mar 23Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts
Mar 02Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate
Jan 13Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%
Oct 04Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?
Sep 28Returns On Capital Are A Standout For Cogstate (ASX:CGS)
Sep 02We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease
Jun 30Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital
Mar 22We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation
Oct 20Cogstate (ASX:CGS) Is Looking To Continue Growing Its Returns On Capital
Jul 23Is Cogstate (ASX:CGS) Using Too Much Debt?
Apr 29What Can The Trends At Cogstate (ASX:CGS) Tell Us About Their Returns?
Mar 14Here's What Cogstate Limited's (ASX:CGS) Shareholder Ownership Structure Looks Like
Feb 21
How Much Is Cogstate's (ASX:CGS) CEO Getting Paid?
Jan 17Can You Imagine How Jubilant Cogstate's (ASX:CGS) Shareholders Feel About Its 214% Share Price Gain?
Dec 05Shareholder Returns
| CGS | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | 1.9% | 7.3% | 0.9% |
| 1Y | -14.2% | 60.7% | 5.7% |
Return vs Industry: CGS underperformed the Australian Healthcare Services industry which returned 60.7% over the past year.
Return vs Market: CGS underperformed the Australian Market which returned 5.7% over the past year.
Price Volatility
| CGS volatility | |
|---|---|
| CGS Average Weekly Movement | 8.1% |
| Healthcare Services Industry Average Movement | 8.1% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: CGS has not had significant price volatility in the past 3 months.
Volatility Over Time: CGS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 158 | Brad O'Connor | www.cogstate.com |
Cogstate Limited, a neuroscience technology company, engages in the creation, validation, and commercialization of digital brain health assessments used in both academic and industry sponsored research. Its cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. The company is also involved in the design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments.
Cogstate Limited Fundamentals Summary
| CGS fundamental statistics | |
|---|---|
| Market cap | AU$226.34m |
| Earnings (TTM) | AU$8.47m |
| Revenue (TTM) | AU$63.13m |
26.7x
P/E Ratio3.6x
P/S RatioIs CGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGS income statement (TTM) | |
|---|---|
| Revenue | US$41.08m |
| Cost of Revenue | US$18.81m |
| Gross Profit | US$22.26m |
| Other Expenses | US$16.75m |
| Earnings | US$5.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | 0.032 |
| Gross Margin | 54.20% |
| Net Profit Margin | 13.42% |
| Debt/Equity Ratio | 1.2% |
How did CGS perform over the long term?
See historical performance and comparison